ANV-600 is under clinical development by Anaveon and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ANV-600’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANV-600 overview
ANV-600 is under development for the treatment of solid tumors including cutaneous melanoma, metastatic squamous or non-squamous non-small cell lung cancer (NSCLC) and recurrent head and neck squamous cell carcinoma (HNSCC). The therapeutic candidate is administered through intravenous route and is a bi-specific fusion protein containing a programmed cell death protein 1 (PD1) binding moiety and an interleukin 2 (IL 2) receptor beta and gamma directed interleukin 2 which is linked to an anti-interleukin 2 antibody with high affinity to IL 2 receptor alpha binding domain of IL 2.
Anaveon overview
Anaveon, a subsidiary of Syncona Ltd, is a clinical stage biopharmaceutical company that develops novel therapeutics for diseases with high unmet needs. The company is headquartered in Basel, Basel-Stadt, Switzerland.
For a complete picture of ANV-600’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
